New Insights into First-Line Conventional Therapies in Rheumatoid Arthritis 

This webinar was organised and funded by Medac.

Disclaimer: The webinar is intended for healthcare professionals only. Prescribing information for Metoject® PEN (methotrexate) is available here. Please consult your local prescribing information as information may vary. Adverse event reporting information can be found at the bottom of this webpage. 

Acknowledgements: Medical writing assistance was provided by Jessica Jinks and Alexander Perkins, EMJ, London, UK.  

This interactive webinar brings together leading international rheumatology experts to explore best practices in first-line therapy for rheumatoid arthritis (RA), with a focus on optimising therapy and improving patient outcomes.

Key topics:   

• Optimising conventional therapeutics in first-line RA therapy   
• Impact of disease-modifying antirheumatic drugs (DMARDs) on blood pressure in patients with RA  
• Gut microbiota’s influence on  conventional synthetic DMARD response   
• Patient education for those undergoing first-line RA therapy 

Chairperson:   

Gouri M. Kodurii^1,2

Speakers:  

Arduino A. Mangoni^3,4

Claire I. Daien⁵

Ricardo J. O. Ferreira^6-9

1. Rheumatology consultant, Southend University Hospital, UK  
2. Director of MSK Research, East of England, UK  
3. Flinders University, Adelaide, Australia  
4. Southern Adelaide Local Health Network, Adelaide, Australia  
5. Centre Hospitalier Universitaire, Université de Montpellier, France  
6. Nursing School of the University of Lisbon (ESEUL), Portugal  

Disclosure:   

Koduri has received honorary speaker fees from Roche, Medac and Boehringer Ingelheim.   

Mangoni has received research funding and honoraria from medac, Marinova Pty Ltd, Tour de Cure, Flinders Foundation, Southern Adelaide Local Health Network, Arthritis Australia, Astra Zeneca, and the Australian Marine Bioproducts Cooperative Research Centre.  

Daïen has received consultancy fees from AbbVie, Abivax, BMS, Fresenius Kabi, Pfizer; has presented at conferences for and/or received research fees from AbbVie, Amgen, BMS, Celltrion, Galapagos, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Roche, Sandoz, Sanofi, UCB; and has had ad hoc engagements with AbbVie, BMS, Celltrion, Fresenius Kabi, Galapagos, Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, Roche-Chugai, UCB.